Trial Profile
Open label multicenter study to assess the efficacy, safety, and tolerability of bosentan in Japanese patients with pulmonary arterial hypertension (PAH) in WHO functional class II.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 10 Jun 2016 New trial record